医学
流行病学
骨关节炎
物理疗法
重症监护医学
梅德林
儿科
内科学
关节病
替代医学
作者
Vicky Duong,Sarah Kobayashi,Kai Fu,Lauren K. King
标识
DOI:10.1016/j.joca.2026.11.001
摘要
AIM: The aim of this review was to summarise the key epidemiological and therapeutic research on osteoarthritis (OA) published between April 2025 and March 2026. METHODS: We conducted a narrative review drawing on a search of the MEDLINE database and an informal survey to OA experts. Studies were eligible if they were published between April 1, 2025, and March 31, 2026, conducted on humans, and published in English. From our search, total of 1305 papers were screened by pairs of two authors, resulting in 97 papers considered for potential inclusion and twenty-nine included. Twenty-one studies were identified by OA experts, of which three additional papers were included. A total of 32 papers were included in the review based on their novelty, quality and relevance to OA epidemiology and therapy (n=18 for epidemiology and n=14 for therapy). We prioritised longitudinal cohort studies for epidemiological papers and randomised controlled trials for therapeutic papers. RESULTS: Findings from epidemiological studies confirmed the role of metabolism and physical inactivity in development and progression of OA, as well as identified potential emerging risk factors of air pollution exposure and the role of endogenous and exogenous hormones. Therapeutic interventions for OA focused on pharmacotherapy interventions, including the repurposing of drugs, methotrexate and metformin. There was new evidence for potential mechanisms of glucagon-like peptide-1 therapies in OA and their cost-effectiveness, in addition to ongoing critical research into new disease-modifying therapies and pain-targeted interventions. One surgical study found that high tibial osteotomy provided structural and symptomatic benefits in selected people. CONCLUSION: Research published during 2025 to 2026 reinforces the multifactorial nature of OA. Most new epidemiological findings require verification before inferring causality, and few new therapies studied are ready for routine adoption. There is still a need for disease-modifying OA drugs in addition to highly effective symptomatic treatments. Meanwhile, implementation of existing first-line OA care and prevention strategies should be prioritised.
科研通智能强力驱动
Strongly Powered by AbleSci AI